Cardiac Imaging

While cardiac ultrasound is the widely used imaging modality for heart assessments, computed tomography (CT), magnetic resonance imaging (MRI) and nuclear imaging are also used and are often complimentary, each offering specific details about the heart other modalities cannot. For this reason the clinical question being asked often determines the imaging test that will be used.

RSS icon
Thumbnail

Energy drinks and sudden cardiac arrest: There’s smoke, and there may be fire

Individuals with underlying heart disease may want to avoid energy drinks going forward, according to a new Mayo Clinic analysis.

artificial intelligence robot evaluates healthcare data

AI-powered platform for arrhythmia detection gains FDA approval

The newly approved DeepRhythm Platform from Medicalgorithmics uses advanced AI to evaluate imaging results and look for signs of cardiac arrhythmias.

Video interview with Peter Monteleone, MD, explaining the primary catheter-based interventional tools used to treat pulmonary embolism (PE).

A cardiologist's guide to treating pulmonary embolism

Interventional cardiologist Peter Monteleone, MD, discussed the primary tools used to treat pulmonary embolism in the cath lab.

Vivek Reddy, MD, Director, Cardiac Arrhythmia Service, and the Leona M. and Harry B. Helmsley Charitable Trust Professor of Medicine in Cardiac Electrophysiology, at Mount Sinai in New York, was involved in most of the late-breaking pulsed field ablation (PFA) trials at the Heart Rhythm Society (HRS) 2024 meeting. He offers an overview of the new data presented and his observations from using PFA. #HRS24 #HRS2024 #PFA #EPeeps

The future of electrophysiology: Reviewing key trends in PFA

Vivek Reddy, MD, was involved in most of the late-breaking pulsed field ablation trials at Heart Rhythm 2024. He spoke to Cardiovascular Business at the conference about those trials and what they mean going forward.

Elutia, a Maryland-based healthcare technology company, has received clearance from the U.S. Food and Drug Administration (FDA) for EluPro, its new biologic envelope specifically designed for patients with implantable pacemakers and defibrillators. It was also cleared for use when implanting other types of devices, including neurostimulators and neuromodulators.

FDA clears new drug-eluting envelope for implantable cardiac devices—CEO sees it as ‘tip of the iceberg’

Elutia, formerly known as Aziyo Biologics, is already targeting additional uses for the newly approved device. 

Video of Peter Monteleone, MD, discusses role of cardiology in pulmonary embolism response teams (PERT). CT image of the heart showing bilateral pulmonary embolism blood clots in the pulmonary arteries leading into the lungs.

Interventional cardiology sees growing role in pulmonary embolism interventions

Peter Monteleone, MD, national director of cardiovascular research at Ascension Health, explains the growing role of interventional cardiology in pulmonary embolism treatment and PERT teams.

The ASNC team at the 2024 AMA meeting, Georgia Lawrence, JD, ASNC director of regulatory affairs; Suman Tandon, MD, FASNC, delegate to the AMA HOD and cardiac imager at NYU Langone; and Kathy Flood, ASNC CEO. #AMA #AMA24 #AMA2024 #AMAHOD #ASNC

ASNC supports AMA effort to limit use of AI in prior authorization decisions

The American Society of Nuclear Cardiology (ASNC) supports an AMA policy that condemns the use AI to make prior authorization decisions rather than a doctor or clinician.

How long do wearable cardiac monitors record data?

Long-term continuous monitoring (LTCM) wearable devices now make up 40% or more of the remote ECG monitoring market due to ease of use and collection of more data.

Displaying 177 - 184 of 1685
Design by Adaptive Theme